Amwill Health Care Limited has obtained a new import registration certificate from the Central Drugs Standard Control Organization (CDSCO) for its FoliColor Oxidative hair colour products. This regulatory approval allows the company to commence the import and commercial sale of the product in India, marking a key step in expanding its consumer portfolio.

The approval, granted on October 9, 2026, pertains specifically to the Black variant of FoliColor Hair Color. The registration certificate, numbered RC/COS-007631, is valid for five years, effective from October 8, 2026, until October 7, 2031, unless suspended or cancelled earlier under applicable rules. The counterparty for this supply arrangement is not a related party.

Regulatory details and validity

The company disclosed this development to the Bombay Stock Exchange (BSE) on October 10, 2026, under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The filing confirms that this is a new grant rather than a renewal or amendment of an existing license.

Strategic impact on operations

According to the company's disclosure, this license is expected to expand Amwill Health Care's product portfolio and contribute to revenue growth. By securing the necessary regulatory clearance for cosmetic imports, the company can now legally bring these oxidative hair colour products into the Indian market for sale.

The move signals a diversification strategy into the personal care segment, leveraging regulatory compliance to unlock new revenue streams. No withdrawal, cancellation, or suspension of the license has been reported at this stage.

Amwill Health Care Limited has approved an aggregate investment of up to ₹3 crore in two SEBI-registered Alternative Investment Fund (AIF) schemes. The decision, taken by the company's Investment Committee on September 25, 2026, aims to support its long-term growth strategy and operational objectives.

The investments will be funded entirely from the company's internal accruals. The disclosure was made to the Bombay Stock Exchange (BSE) under Regulation 30 of the SEBI Listing Regulations, read with the SEBI Master Circular dated January 30, 2026. The transaction does not involve any related party dealings.

Investment breakdown

The Investment Committee approved two distinct subscriptions, each capped at ₹1.50 crore. The first allocation is directed toward the Vivriti Vihaan Trust, while the second targets the Neo Income Plus Fund III. Both entities are registered with the Securities and Exchange Board of India (SEBI).

The company stated that the subscription to Neo Income Plus Fund III units is proposed to be made in the ensuing months. The move reflects a strategic deployment of surplus capital into structured credit and income-generating instruments rather than traditional equity or debt markets.

Regulatory compliance and governance

This approval follows a preliminary sanction granted by the Investment Committee during its meeting on August 8, 2026. The final execution approval was formalized at the September 25, 2026 meeting. The disclosure ensures transparency regarding the utilization of internal funds for external financial instruments.

The filing confirms that these transactions are arm's length and do not constitute related party transactions, adhering to standard corporate governance norms. The details of this disclosure are available on the company's official website.